The phase 3 MATISSE study of RSVpreF given to pregnant women in order to protect their babies after birth found that the vaccine had efficacy of 81.8% in preventing lower respiratory tract infections caused by RSV in the first 90 days of life, falling to 69.4% at six months.
It also reduced infants’ risk of needing medical intervention for an RSV infection by around half in the first six months, although that was not a statistically significant difference.
